HavrdovaEArnoldDLCohenJA, et al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology2017; 89(11): 1107–1116.
2.
ColesAJCohenJAFoxEJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology2017; 89(11): 1117–1126.
3.
BartonJHardyTARimintonS, et al. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology2017; 88(10): 1004–1006.
4.
HaghikiaADendrouCASchneiderR, et al. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol2017; 16: 104–106.
5.
WehrumTBeumeLAStichO, et al. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. Neurology2018; 90: e601–e605.
6.
RinaldiFFederleLPuthenparampilM, et al. Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy. Neurol Neuroimmunol Neuroinflamm2018; 5: e420.
7.
HyunJ-WKimYKimG, et al. Severe B-cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis. Mult Scler2019; 25: 1942–1945.
8.
BlairPANoreñaLYFlores-BorjaF, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity2010; 32: 129–140.
9.
Flores-BorjaFBosmaANgD, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med2013; 5(173): 173ra23.
